SCHEMBL5012718

SCHEMBL5012718

Ic1ncc(-c2cccnc2)o1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.57
KDM4E B2RXH2 3/20 0.57
HPGD P15428 3/20 0.57
HSD17B10 Q99714 2/20 0.57
NPC1 O15118 1/20 0.57
RAB9A P51151 1/20 0.57
CYP3A4 P08684 7/20 0.51
CYP2C19 P33261 6/20 0.51
CYP2D6 P10635 5/20 0.51
CYP2C9 P11712 5/20 0.51
CYP2E1 P05181 4/20 0.51
CYP2B6 P20813 4/20 0.51
CYP2A6 P11509 14/20 0.50
CYP1A2 P05177 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.48
LMNA P02545 1/20 0.44
TP53 P04637 1/20 0.44
MAPT P10636 1/20 0.44
ALOX15 P16050 1/20 0.44
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5012738 0.79 NPC1 (0.51) ALDH1A1KDM4EHPGDHSD17B10NPC1
SCHEMBL15083065 0.78 ALDH1A1 (0.57) ALDH1A1KDM4EHPGDHSD17B10NPC1
SCHEMBL9342867 0.78 ALDH1A1 (0.57) ALDH1A1KDM4EHPGDHSD17B10NPC1
SCHEMBL12920039 0.77 ALDH1A1 (0.53) ALDH1A1KDM4EHPGDHSD17B10NPC1
SCHEMBL4882549 0.76 RAB9A (0.87) ALDH1A1KDM4EHPGDHSD17B10NPC1
SCHEMBL27768674 0.74 FAAH (0.55) ALDH1A1KDM4EHPGDHSD17B10NPC1
SCHEMBL14395287 0.74 CYP3A4 (0.59) ALDH1A1KDM4EHPGDHSD17B10NPC1
SCHEMBL4881571 0.73 RAB9A (1.00) ALDH1A1KDM4EHPGDHSD17B10NPC1
SCHEMBL2724813 0.73 ALDH1A1 (0.55) ALDH1A1KDM4EHPGDHSD17B10NPC1
SCHEMBL13848617 0.71 ALDH1A1 (0.50) ALDH1A1KDM4EHPGDHSD17B10NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080113983-A1 Nicotinic Acetylcholine Receptor Ligands ASTRAZENECA AB (SE) 2008-05-15 US disclosed
US-20080113983-A1 Nicotinic Acetylcholine Receptor Ligands ASTRAZENECA AB (SE) 2008-05-15 US disclosed
US-20080113983-A1 Nicotinic Acetylcholine Receptor Ligands ASTRAZENECA AB (SE) 2008-05-15 US disclosed
EP-1831231-A1 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AstraZeneca AB (SE) 2007-09-12 EP disclosed
WO-2006065209-A1 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS ASTRAZENECA AB (SE) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113983-A1 Nicotinic Acetylcholine Receptor Ligands CHRNA1, CHRNA2, CHRNB1 ALDH1A1 577/4885KDM4E 4191/4885HPGD 1807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.